Compare Incyte Corporation (INCY) vs Paychex, Inc. (PAYX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Paychex, Inc. — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while Paychex, Inc. trades at $103.98 (market cap $37.19B). The key difference: Paychex, Inc. is the larger of the two by market cap, and Paychex, Inc. pays a 4.56% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Paychex, Inc. for 56 Days on average.
| INCY | PAYX | |
|---|---|---|
Market Cap | $22.85B | $37.19B |
Volume | 1,927,029 | 3,344,316 |
Sector | Health | Industrials |
52-Week High | $129.93 | $128.59 |
52-Week Low | $83.80 | $85.57 |
Typical Hold Time | 33 Days | 56 Days |
Enterprise Value | $18.35B | $40.87B |
Dividend Yield | — | 4.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.
Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.
Paychex (PAYX) trades at $104.46, up 2.87% on the day, with a mixed technical outlook showing a bullish overall signal but bearish moving averages. The company continues to deliver strong fundamentals, beating earnings estimates for the last three quarters with a net income margin of 27.35% and robust ROE of 47.06%. Recent news highlights earnings beats but also concerns over stock performance and dividend sustainability despite a recent 5-star rating from Newsweek.
The stock presents a cautious opportunity with a consensus price target of $111 offering ~6% upside, but risks include a high P/E of 20.73, significant debt increase, and sensitivity to labor market trends. Investor sentiment is divided, with analyst consensus leaning Hold, reflecting balanced growth prospects against valuation and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →
